Ethypharm Inc. is recalling one lot of M-Eslon (morphine sulfate) extended release (ER) capsules because some bottles labelled as M-Eslon 30 mg ER may contain 60 mg capsules. This issue could lead to patients receiving a 60 mg dose instead of their prescribed 30 mg dose, which could result in an overdose and pose serious health risks. M-Eslon is a prescription opioid drug used by adults for long-term pain management when pain is severe enough to require daily, around-the-clock painkillers and other treatment options are not able to treat the pain. The 60 mg capsule has "60" and "M-ESLON" printed on it. The capsule has an opaque orange cap and a clear bottom. The 30 mg capsule has "30" and "M-ESLON" printed on it. The capsule has an opaque pink cap and a clear bottom. Taking too much morphine or suddenly increasing the dose could potentially lead to an overdose, which can be life-threatening. Symptoms of morphine overdose may include: confusion, dizziness, drowsiness, difficulties waking up, small (pinpoint) pupils, slow heartbeat, slow and difficult breathing, cold and clammy skin, fainting, seizure, coma and death. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to stop this issue from reoccurring. The Department will inform the public if any new health risks are identified.